Immix Biopharma Completes 3rd NXC-201 Engineering Batch at its U.S. CAR-T Manufacturing Site | Markets Insider

Immix Biopharma completed its 3rd engineering batch of NXC-201, a BCMA-targeted CAR-T cell therapy, at its California facility, marking a milestone for U.S. manufacturing capability. NXC-201, with a 100% response rate in AL Amyloidosis patients, aims to expand CAR-T therapy access, potentially becoming the first outpatient CAR-T.